Tickers

1. Composite Trajectory Verdict

Given CERT's software-and-services model with significant acquisition-related intangibles and recurring contingent consideration liabilities, the income statement and cash flow statement carry the most weight for assessing trajectory; the balance sheet reflects acquisition accounting and financing choices more than operating performance.

Composite Trajectory: Mixed

Annual results (2023–2025) show consistent improvement: revenue grew 18% cumulatively, operating income swung from a $40.8M loss to a $21.0M gain, and operating cash flow rose 16% to $96.3M. However, the most recent quarterly period (H1 2026 vs. H1 2025) shows deterioration in continuing operations — net loss widened from a $3.0M gain to a $17.9M loss and operating cash flow fell 33% to $15.6M — driven by a $13.1M contingent consideration expense increase and a $65.5M pretax loss on the Regulatory and Medical Writing divestiture. The annual and quarterly series point in opposite directions.

2. Red Flags

• GAAP net loss persists despite positive operating income: FY 2025 operating income of $21.0M was erased by $19.7M interest expense and a $9.2M tax provision (effective rate 120.9%), leaving a $1.6M net loss (10-K 2025-12-31, Consolidated Statements of Operations).
• Widening GAAP vs. non-GAAP gap: Adjusted EBITDA of $134.5M vs. GAAP net loss of $1.6M in FY 2025; the reconciliation includes $33.1M equity compensation, $56.2M acquisition intangible amortization, and $3.6M contingent consideration fair value changes (10-K 2025-12-31, MD&A non-GAAP measures).
• Recurring “non-recurring” contingent consideration swings: Fair value adjustments hit G&A in each of the last three years (+$8.1M in 2024, -$3.6M in 2025, +$24.1M in 2023) and drove a $13.1M expense increase in H1 2026 alone (10-K 2025-12-31, MD&A G&A; 10-Q 2026-06-30, MD&A G&A).
• Operating cash flow decline in H1 2026: Continuing operations cash flow dropped to $15.6M from $23.3M in H1 2025, despite 2% revenue growth (10-Q 2026-06-30, MD&A Liquidity and Capital Resources).
• Share repurchases while levered and loss-making: $42.6M repurchased in FY 2025 and $57.4M in H1 2026 (exhausting the $100M authorization) while carrying $294M term debt and posting GAAP net losses (10-K 2025-12-31, MD&A Liquidity; 10-Q 2026-06-30, MD&A Liquidity).
• Large divestiture loss: $65.5M pretax loss on sale of Regulatory and Medical Writing business in Q2 2026, producing a $49.2M after-tax loss from discontinued operations for the six months ended June 30, 2026 (10-Q 2026-06-30, MD&A Results of Operations).
• Valuation allowance growth: Deferred tax asset valuation allowance rose to $29.4M at Dec 31, 2025 from $24.0M a year earlier, primarily against foreign tax credits and foreign NOLs (10-K 2025-12-31, Note 15 Income Taxes).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Annual GAAP results improved markedly over 2023–2025: revenue rose from $354.3M to $418.8M (+18%), operating income improved from -$40.8M to +$21.0M, and net loss narrowed from -$55.4M to -$1.6M (10-K 2025-12-31, Consolidated Statements of Operations). Gross margin was stable near 60–61%. In contrast, the comparable six-month period for continuing operations deteriorated: revenue grew only 2% to $187.4M, but net income swung from a $3.0M gain to a $17.9M loss, driven by a 41% jump in G&A (to $50.9M) largely from the $13.1M contingent consideration expense increase, plus higher R&D (+13%) and S&M (+7%) (10-Q 2026-06-30, MD&A Results of Operations). The quarterly trajectory is therefore negative while the annual trajectory remains positive.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Annual operating cash flow grew steadily: $82.8M (2023) → $80.5M (2024) → $96.3M (2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). Free cash flow (operating cash flow less capex and capitalized software) was approximately $67.5M, $59.5M, and $69.7M respectively. However, H1 2026 continuing operations cash flow fell to $15.6M from $23.3M in H1 2025, a 33% decline attributed to lower cash-adjusted net income, increased prepaid/other asset cash usage, and reduced accounts receivable collections (10-Q 2026-06-30, MD&A Cash Flows). Investing outflows moderated after the Chemaxon acquisition (FY 2024: $112.4M vs. FY 2025: $26.6M), while financing outflows surged in H1 2026 to $82.3M (vs. $44.7M) due to $57.4M share repurchases and $6.9M contingent consideration payments (10-Q 2026-06-30, MD&A Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Stable

Year-end 2024–2025 showed modest deleveraging and cash accumulation: cash rose to $189.4M from $179.2M; long-term debt (net) declined to $290.1M from $292.4M; total liabilities fell to $493.8M from $516.4M; stockholders’ equity was flat at ~$1.06B despite a $48.5M increase in treasury stock from repurchases (10-K 2025-12-31, Consolidated Balance Sheets). Goodwill grew to $773.3M from $757.0M with the Chemaxon acquisition. In the first half of 2026, cash declined to $184.1M, goodwill dropped to $718.1M (reflecting the Regulatory and Medical Writing divestiture), and long-term debt edged down to $294.0M (10-Q 2026-06-30, Consolidated Balance Sheets). The balance sheet has been stable overall, with changes driven by acquisition/divestiture accounting and share repurchases rather than operating performance.

6. Data Gaps

• Standalone quarterly income statements and cash flows for Q1 2026, Q3 2025, and Q4 2025 (only six-month and full-year aggregates are provided in the filings).
• Full balance sheet as of June 30, 2026 (the provided XBRL excerpt is truncated; total assets, total liabilities, and equity detail are not fully visible).
• Segment-level revenue and profit (the company reports a single segment; no finer breakdown is disclosed).
• Organic revenue growth rate for H1 2026 (the 10-K provides organic revenue for FY 2025 only).
• Contingent consideration liability roll-forward for H1 2026 (only the expense impact is discussed; the balance sheet movement is not fully detailed in the excerpt).